Harvard Apparatus Regenerative Technology, Inc.
Close on Oct 19, 2026
- Market cap
- $38.92M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2022 Ended Sep 30, 2022 | Nov 14, 2022 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 4, 2022 | During market hours | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | Apr 1, 2022 | Before market open | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Nov 15, 2021 | During market hours | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 13, 2021 | During market hours | – | – | – |
| Q1 FY2021 Ended Mar 31, 2021 | Apr 13, 2021 | During market hours | – | – | – |
| Q3 FY2020 Ended Sep 30, 2020 | Nov 13, 2020 | During market hours | – | – | – |
| Q2 FY2020 Ended Jun 30, 2020 | Aug 13, 2020 | During market hours | – | – | – |
| Q1 FY2020 Ended Mar 31, 2020 | May 14, 2020 | During market hours | – | – | – |
| Q4 FY2019 Ended Dec 31, 2019 | Mar 27, 2020 | During market hours | – | – | – |
| Q3 FY2019 Ended Sep 30, 2019 | Nov 12, 2019 | Before market open | – | – | – |
| Q2 FY2019 Ended Jun 30, 2019 | Aug 13, 2019 | Before market open | – | – | – |
Press releases
Announcements Harvard Apparatus Regenerative Technology filed with the SEC
Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant at Mayo Clinic
Regulation FD disclosure · EX-99.1 to Form 8-K
Name to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN)
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Announces $6 Million Financing to Advance Clinical Trial
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces Chairman and CEO Transition
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
Other events · EX-99.1 to Form 8-K
New Publication Demonstrates Rapid Esophageal Regeneration using the Biostage Esophageal Implant
Other events · EX-99 to Form 8-K
Biostage Reports Corporate Highlights and Third Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Biostage Reports Corporate Highlights and Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Biostage Reports Q1 2022 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Biostage Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Preliminary Injunction Order Requiring its Insurance Carrier to Continue Paying for Defense.
Other events · EX-99.1 to Form 8-K
“Meet the Founder, New Chairman and Interim CEO” Webinar
Other events · EX-99.2 to Form 8-K
Scientific Proof of Esophageal Regeneration Image from JTO Clinical and Research Reports, August 2021, Wigle et al
Regulation FD disclosure · EX-99.1 to Form 8-K
HOLLISTON, Mass., November 15, 2021 /PRNewswire/
Results of operations · EX-99.1 to Form 8-K